GCL
EFTRW

Glazer Capital LLC’s eFFECTOR Therapeutics, Inc. Warrant EFTRW Stock Holding History

Glazer Capital LLC’s Portfolio EFTRW Stock Details EFTRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-164,259
Closed -$164K – 1000
2021
Q2 		$164K Buy
+164,259
New +$133K ﹤0.01% 760

Other funds holding EFTRW

AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Glazer Capital LLC's EFTRW Position: Q3 2021 in Review

Glazer Capital LLC sold out of eFFECTOR Therapeutics, Inc. Warrant (EFTRW) in Q3 2021, closing a stake of 164,259 shares — an estimated $164K sold.

Glazer Capital LLC first reported a position in EFTRW in Q2 2021 and held it in 1 quarter. The position peaked at $164K in Q2 2021. 21 funds tracked by Wall St. Rank hold EFTRW as of Q3 2021.

  • Glazer Capital LLC reported no remaining eFFECTOR Therapeutics, Inc. Warrant position as of Q3 2021 after selling out during the quarter.
  • Glazer Capital LLC sold 164,259 eFFECTOR Therapeutics, Inc. Warrant shares in Q3 2021, an estimated $164K.
  • Glazer Capital LLC first reported a position in eFFECTOR Therapeutics, Inc. Warrant in Q2 2021 and held it in 1 quarter.
  • Glazer Capital LLC's eFFECTOR Therapeutics, Inc. Warrant position peaked at $164K in Q2 2021.
  • 21 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Warrant as of Q3 2021.

Based on Glazer Capital LLC's 13F filing for Q3 2021, filed 15 Nov 2021.